Abstract
One of the most rapidly advancing areas of gene therapy is vector development. For the majority of gene therapy procedures, efficient and selective transduction would provide safe and more effective treatments at optimal vector doses. Advances in vector targeting strategies have been rapid within the field of DNA-based viruses, particularly adenovirus (Ad) and more recently adeno-associated virus (AAV) based vectors. Vector targeting at the level of virus: cell interaction can be achieved using both non-genetic and genetic methodology. Non-genetic approaches typically utilise bispecific antibodies that both neutralise wild-type virus tropism and provide a new cell binding capacity. For genetic targeting strategies, the virus capsid can be engineered to express foreign ligands that target selected receptors in the absence or presence of additional modification to ablate the virusnatural tropism. This review covers technological advances that have led to targeting of Ad and AAV and highlights the potential for these ‘designer’ viruses for future gene-based therapeutics.
Keywords: Tropism-Modified Adenoviral, Adeno-Associated, Viral Vectors, Gene Therapy, PSEUDOTYPING, TROPISM EXPANSION, TARGETING AAV
Current Gene Therapy
Title: Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Volume: 2 Issue: 3
Author(s): Stuart A. Nicklin and Andrew H. Baker
Affiliation:
Keywords: Tropism-Modified Adenoviral, Adeno-Associated, Viral Vectors, Gene Therapy, PSEUDOTYPING, TROPISM EXPANSION, TARGETING AAV
Abstract: One of the most rapidly advancing areas of gene therapy is vector development. For the majority of gene therapy procedures, efficient and selective transduction would provide safe and more effective treatments at optimal vector doses. Advances in vector targeting strategies have been rapid within the field of DNA-based viruses, particularly adenovirus (Ad) and more recently adeno-associated virus (AAV) based vectors. Vector targeting at the level of virus: cell interaction can be achieved using both non-genetic and genetic methodology. Non-genetic approaches typically utilise bispecific antibodies that both neutralise wild-type virus tropism and provide a new cell binding capacity. For genetic targeting strategies, the virus capsid can be engineered to express foreign ligands that target selected receptors in the absence or presence of additional modification to ablate the virusnatural tropism. This review covers technological advances that have led to targeting of Ad and AAV and highlights the potential for these ‘designer’ viruses for future gene-based therapeutics.
Export Options
About this article
Cite this article as:
Nicklin A. Stuart and Baker H. Andrew, Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy, Current Gene Therapy 2002; 2 (3) . https://dx.doi.org/10.2174/1566523023347797
DOI https://dx.doi.org/10.2174/1566523023347797 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design <i>In Vitro</i> Effects of Propofol on Cytotoxic, Apoptotic and PI3K-Akt Signaling Pathway Genes on Brain Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs Cellular Photodynamic Toxicity of Hematoporphyrin in Various Nanocarrier Systems
Current Nanoscience The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Subject Index to Volume 4
Current Pharmaceutical Biotechnology Molecular Mechanisms Mediating Nociceptin/Orphanin FQ Receptor Signaling, Desensitization and Internalization
Current Molecular Pharmacology Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Meet Our Editorial Board Member
Current Drug Discovery Technologies Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology